Baxter’s Split Into Two Companies Bears Similarity To Abbott’s Biopharma Spinout

The Illinois-based company will spin out its biopharma business by mid-2015, creating two public companies that will cater to vastly different markets. Yet, both companies are expected to boast strong balance sheets and be in position to make acquisitions.